Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Phase III GZR18 Injection for Weight Reduction
CTR20254659Phase 3Active
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bofanglutide in Overweight, obesity, sponsored by Gannex Pharma Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
bofanglutide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20254659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254659.